Merck and AbbVie: Two High-Performing Dividend Stocks in Healthcare
In 2026, Merck (MRK) and AbbVie (ABBV) have outperformed the broader market amid a rebound in healthcare sector performance. Merck's shares rose by 39%, while AbbVie gained 24% year-to-date compared to an S&P 500 increase of about 12%. Both companies are highlighted for their strong financial results and long-term growth potential. Merck reported second-quarter revenue up 5% year-over-year, driven by its Keytruda franchise and HPV vaccines. The company is preparing for the loss of patent exclusivity on Keytruda in 2028 but expects to retain market share with a subcutaneous version called Qlex. AbbVie also delivered strong results, reporting revenue growth of 10.2% year-over-year, driven by its top-selling drugs Skyrizi and Rinvoq. Both companies have robust pipelines and solid dividend programs. Merck offers a forward yield of 2.37%, with consistent payout increases over the past decade. AbbVie's key products are protected from biosimilar competition until at least 2033, giving it time to develop future growth strategies.
Topics: Healthcare Pharmaceuticals Stock Market